Articles tagged with Antibodies
A study of 77 lactating parents found a higher prevalence of anti-SARS-CoV-2 antibodies in breast milk among unvaccinated mothers, suggesting potential protection against COVID-19. The study also identified a link between vaccine-induced immunity and increased neutralizing activity in human milk.
Virginia Tech researchers have developed a miniature optical fiber treatment device that delivers cancer immunotherapeutic antibodies while monitoring tumor impedance to track treatment efficacy. The device elicits sustained anti-tumor immunity with complete tumor shrinkage in multiple tumor models.
Researchers found that older individuals produce higher levels of protective antibodies after infection or vaccination, providing better defense against emerging variants. Antibodies from infected individuals 50+ years old reacted strongly to the Delta variant, outperforming those from vaccinated adults under 50.
Researchers aim to make drug purification more efficient and scalable by understanding unwanted element interactions. They explored ligand-surface interactions using NMR spectroscopy and simulations.
Researchers have detected antibodies primarily made in response to mucous membrane infections, not typically thought of as a blood and liver infection, in study participants with malaria. The discovery provides new insight into the human body's response to malaria and may help identify new ways to treat or develop vaccines.
Researchers at Duke University and UNC-Chapel Hill have identified a new antibody that can block infections and minimize symptoms against a broad array of coronaviruses, including SARS-CoV-1 and SARS-CoV-2. The antibody was tested in animal models and found to be effective in protecting mice against developing severe lung symptoms.
Researchers at Johns Hopkins Medicine found that antibody levels against SARS-CoV-2 stay higher in people who were infected by the virus and then received protection from mRNA vaccine compared to those who only got vaccinated. A longer interval between virus exposure and first vaccine dose may enhance antibody response.
A Brazilian study demonstrates that a hyperimmune serum consisting of purified antibody fragments produced in horses can be an efficient approach to combat covid-19. The neutralizing activity of the sera has been proved to be high against the P.1 (Gamma) and P.2 variants, improving animal clinical conditions in hamsters.
Researchers developed a novel sensor that can detect SARS-CoV-2 proteins without antibodies, giving results within minutes. The technology enables rapid diagnostics for Covid-19 and future pandemics, reducing economic loss.
Cadmium exposure has been linked to an increased risk of developing allergies, particularly asthma, in children. Researchers found that gut bacteria over-produce an enzyme degrading vitamin D after cadmium ingestion, mimicking a deficiency, leading to enhanced allergic reactions.
A new study found that COVID-19 can trigger severe psychiatric symptoms in adolescents, with anti-neural antibodies playing a potential role. Two patients with mild/asymptomatic COVID developed suicidal thoughts and paranoid fears, while another patient without prior psychiatric history recovered fully after treatment.
A study of young Swedish adults found that over one in four had SARS-CoV-2-specific antibodies, but fewer had measurable levels of memory B and T cells compared to other age groups. The researchers will continue to study long COVID and vaccination effects on immunity.
Researchers discovered that a lower dose of the first shot, followed by a full-dose booster, significantly improved SARS-CoV-2 vaccine potency in mice. This approach, which involves an extended prime-boost interval, may lead to more robust and durable immune responses.
A new study from Karolinska Institutet finds that two vaccine doses increase antibody levels in the airways after COVID-19, while a second dose after recovery also boosts levels. The results highlight the importance of completing vaccination with a second dose to achieve optimal immune responses and reduce transmission.
A new study published in Science Translational Medicine found that male placentas have increased immune activation and receive fewer anti-COVID antibodies from their mothers. This may help protect male fetuses but pose risks to the fetus and child.
Patients with multiple myeloma often mount a poor antibody response to COVID-19 vaccines and have a weak T cell response, underscoring the need for booster vaccination and safety precautions. Researchers found that these patients are at high risk of severe COVID-19 infection.
Researchers will focus on understanding the disease, identifying B cell characteristics and plasma cells that create attacking antibodies. The study aims to enhance knowledge of SLE pathogenesis and differences in clinical manifestations, outcomes, and therapeutic responses.
A study by Northwestern University scientists has shown that coronavirus vaccines and prior infections can provide broad immunity against other, similar coronaviruses. The findings build a rationale for universal coronavirus vaccines.
A team of scientists has found that IgA antibodies, a natural defense substance in the human body, can limit the fitness of benign bacteria in the intestine. This discovery helps maintain a delicate balance between the human organism and the intestinal flora.
Breast milk from Mennonite moms on farms contains higher concentrations of IgA antibodies against food allergens and bacteria associated with farm animals. Babies born to these mothers show reduced rates of atopic diseases, suggesting a protective factor passed on through breast milk.
Researchers found that asymptomatic patients may not produce significant IgG antibodies, but rather a different kind of antibody count that can indicate disease severity. The study suggests using the ratio of these two counts as a marker to determine if a person has had COVID-19.
Patients with strong antibody responses against SARS-CoV-2 had low viral RNA levels and survived the illness. The study supports personalized treatment with exogenous antibodies for those with absent or low endogenous antibodies levels.
A study published in JAMA Oncology found that the type of cancer treatment affects the vaccine response, with chemotherapy resulting in lower antibody levels. Vaccination is still recommended for cancer patients, but optimal protection requires ongoing measures.
Researchers at Uppsala University found that allergic stimulation activates mast cell precursor cells, which can produce cytokine IL-13 contributing to asthma development. This challenges the idea that only mature immune cells are involved in immune reactions.
Researchers at the University at Buffalo have developed a new treatment that pairs essential proteins with lysophosphatidylserine to build immune tolerance and prevent antibody development, potentially treating autoimmune disorders and allergies.
Pediatric transplant recipients have a more robust immune response to COVID-19 vaccines, achieving higher antibody levels after two doses compared to adult counterparts. This study suggests that the standard two-dose regimen may be safe and effective in pediatric transplant recipients.
Researchers developed an Internet information system, virusMED, to provide a comprehensive picture of viruses' most important regions. The database contains over 800 strains from 75 different families, including SARS-CoV-2, influenza, Ebola, and HIV-1, enabling scientists to respond quickly and effectively against the next pathogen.
Researchers identified five specific mutations prevalent in Delta Plus infections compared to Delta, highlighting the need for expanded antiviral tools. The findings provide clues on how the virus mutates and evade antibodies produced from previous COVID-19 infections or vaccinations.
Researchers at the Rosalind Franklin Institute have developed nanobodies from llama antibodies that can effectively target SARS-CoV-2 virus. These nanobodies were able to significantly reduce signs of COVID-19 disease in infected animal models and show promise as a new treatment option.
Researchers identify structure and interaction between HCV E2 protein and CD81 receptor, revealing acidic conditions enhance binding and facilitate cell entry. This discovery provides new leads for developing an HCV vaccine by targeting specific antibodies against the virus.
Researchers at the University of Illinois found that antibodies from people infected with the original COVID-19 strain do not effectively bind to newer variants. This has implications for vaccine efficacy and the design of possible boosters.
Researchers at Karolinska Institutet discovered that B cells choose between cell fates to balance acute and memory responses. This understanding could optimize vaccines against viruses or other pathogens.
A Michigan Medicine study found that most patients with mild COVID-19 infections produce antibodies that persist and protect them from reinfection for up to six months. Nearly 90% of participants produced spike and nucleocapsid antibody responses, and all but one had persistent antibody levels at follow-up.
Researchers investigated antibody response to Pfizer-BioNTech vaccine in 117 allogeneic hematopoietic stem cell transplant recipients. The study aimed to assess vaccine safety and immune response in this population. Key findings were not reported in the article.
A new study found that people hospitalized with COVID-19 have elevated levels of autoimmune antibodies in their blood, which are strongly linked to disease severity. Patients with high levels of these autoantibodies were five to seven times more likely to develop severe disease than those with stable antibody levels.
A new study published in Science identifies a specific molecule, C1q, that plays a key role in the long-term effects of traumatic brain injury. The researchers found that an antibody treatment could prevent the development of negative outcomes such as sleep disruption and inflammation.
A Tohoku University research group discovered that Peyer's patches and specific bacteria facilitate the transfer of maternal IgA to breastmilk, boosting newborn immunity. This finding has significant implications for developing probiotics to improve breastfeeding quality.
Researchers have created a new technology to enhance therapeutic antibodies' ability to attack blood cancer cells by leveraging the human immune system. This approach combines IgM and IgG antibodies, resulting in a single molecule with increased complement activation.
The Delta variant's ability to evade neutralizing antibodies and its increased infectivity have contributed to its spread, making vaccination and infection control crucial in the post-vaccination era. The variant was found to be more efficient at replicating and spreading than other variants, giving it a selection advantage.
A new study from the University of Virginia Health System found that Moderna's vaccine produced higher antibody levels than Pfizer's, especially in older subjects. The researchers caution that measuring antibody levels does not necessarily predict vaccine effectiveness.
The study found SARS-CoV-2 antibodies in 44% of blood donors aged 16 to 64 in Kenya. The results suggest that the virus may have circulated in the country before widespread reporting began.
Researchers compared antibody responses in adults receiving Pfizer/BioNTech and Moderna COVID-19 vaccines. The study found differences in antibody responses among young and older adults. Younger recipients showed higher antibody levels after vaccination.
A study found that people who form antibodies against the folded receptor binding domain (RBD) of the SARS-CoV-2 spike protein are protected from infection. However, 20% of those who recovered from Covid-19 fail to develop these antibodies.
Researchers at Washington University School of Medicine found that COVID-19 vaccination elicited a response in nearly nine out of ten people with weakened immune systems. However, the responses were only about one-third as strong as those mounted by healthy people. Despite this, the discovery is encouraging news for a population at hig...
A study published in the American Journal of Transplantation found that Covid-19 vaccines stimulate different immune responses in organ transplant patients. While antibody tests alone are insufficient, combining vaccines with T cell analyses provides better protection.
Research from the University of Florida found that COVID-19 vaccination significantly increases antibodies against SARS-CoV-2 in breast milk, providing passive immunity to newborns. The study suggests that vaccinated mothers can help protect their babies from COVID-19 illness.
Researchers at WashU Medicine have identified two antibodies that protect animals from disease caused by alphaviruses, which could form the basis of treatments or serve as a template for a universal vaccine. The antibodies worked against all tested alphaviruses and prevented arthritis and brain infections in animals.
Researchers at Rice and Baylor are expanding their efforts to halt bone cancer metastasis using a molecule targeting osteoporosis and HER2 protein. Their goal is to improve drug concentration at tumor sites, inhibit secondary metastasis, and explore the therapeutic effect mechanism.
A Rutgers study found that people with severe or prolonged COVID-19 have higher antibody levels against the virus. The study of 831 participants showed that immune responses vary by symptom severity, with those having persistent symptoms producing more antibodies.
Researchers at Massachusetts General Hospital have identified two separate genetic alterations that enable triple-negative breast cancer cells to develop resistance to a highly effective drug. The findings could help improve therapy and prolong survival for patients with this aggressive form of breast cancer.
A study found that mRNA vaccine recipients with prior SARS-CoV-2 infection experienced more severe symptoms after vaccination. The study suggests vaccine type may influence symptom severity in individuals with a history of COVID-19 infection.
Scientists have repurposed CRISPR to identify antibodies in patient blood samples, demonstrating a new class of medical diagnostics. The technique uses customizable proteins attached to Cas9, which assemble on a microchip to bind to specific DNA sequences, allowing for fast and accurate detection.
This observational study evaluates the concentration of SARS-CoV-2 antibodies in breast milk of lactating women who received mRNA vaccines. The findings suggest a correlation between serum antibody levels and breast milk antibody concentrations.
Researchers found that a second dose of the Pfizer vaccine, especially in those with previous SARS-CoV-2 infection, dramatically increased virus variant neutralising antibody responses. This additional boost increases potential protection against existing and future variants of concern.
Researchers found shared clones of antibody-producing white blood cells among COVID-19 survivors and vaccinated individuals, targeting the viral surface 'spike' protein. This discovery could help design more effective vaccines and therapies against emerging variants.
Researchers evaluated antibody levels after Pfizer/BioNTech vaccine in previously infected and uninfected individuals, finding a significant increase in SARS-CoV-2 spike immunoglobin G antibodies. The study suggests the vaccine effectively boosts immunity in those who have already been infected.
A study found that SARS-CoV-2 antibodies remained stable or increased in healthcare workers seven months after infection, indicating potential protection from pre-existing antibodies against common cold coronaviruses. The results suggest that individuals with higher levels of anti-HCoV IgG and IgA had lower susceptibility to COVID-19.
A recent study published in Transplant Infectious Disease found that COVID-19 vaccination provides strong protection against the virus for solid organ transplant recipients, with an almost 80% reduction in symptomatic cases. The study examined data from over 2,150 transplant patients and showed that nearly 70% of vaccinated patients re...
Researchers identified two proteins, HMW1 and HMW2, that stimulate protective immunity against diverse NTHi strains. Immunization with these proteins provides protection against bacterial colonization by other strains, highlighting the vaccine potential for a nontypeable Haemophilus influenzae vaccine.
Researchers analyzed patient specimens and clinical trial data from thousands of patients to assess the importance of immune cell molecules called Fc gamma receptors (FCGRs) in the therapeutic efficacy of two antibody drugs. High levels of FCGR2B on tumor cells were found to prevent rituximab efficacy, while obinutuzumab was not impact...